Physician profile
Jason Suh
NPI 1538491212
$11,078.22
in general payments reported to CMS, 2019-2025
21 companies · $1,785 in 2025
The $1,785 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $2,949 · 2021: $657 · 2022: $2,085 · 2023: $41.06 · 2024: $3,374 · 2025: $1,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,788 · Food and Beverage: $296 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,787.50 |
| Food and Beverage | $296.12 |
| Education | $116.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,892.55 | 2020-2025 | Imfinzi, Lynparza |
| Beigene USA, INC. | $2,194.34 | 2020-2024 | Brukinsa |
| Janssen Biotech, INC. | $1,931.18 | 2019-2024 | Darzalex, Talvey, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $1,562.50 | 2025 | Ninlaro |
| Janssen Scientific Affairs, LLC | $1,515.00 | 2022 | |
| Beigene, LTD. | $525.00 | 2021 | |
| Adc Therapeutics America, INC. | $125.00 | 2025 | |
| Daiichi Sankyo INC. | $68.67 | 2020-2025 | Enhertu |
| Pfizer INC. | $65.00 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $63.26 | 2020-2021 | |
| Seagen INC. | $51.37 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.43 | 2021-2022 | |
| Eisai INC. | $25.69 | 2024 | |
| Lilly USA, LLC | $15.23 | 2024 | Verzenio, Jaypirca |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Suh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.